Upgrade to SI Premium - Free Trial

UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

September 16, 2026 8:47 AM
UBS analyst David Dai reiterated a Buy rating and $33.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments